The acquisition will help Medtronic to expand its capabilities in the modulation of brain function, an important field of medicine.
Based in Eindhoven, The Netherlands, Sapiens SBS is involved in developing DBS system that features an advanced DBS lead with 40 individual stimulation points.
The DBS system was designed to allow more precise stimulation of the intended target in the brain, which may result in reduced procedure time and fewer stimulation-induced side effects.
Medtronic will use Sapiens facility in Eindhoven as a global research and development center for Neuromodulation business to enhance existing R&D operations.
Medtronic Brain Modulation business vice-president and general manager Lothar Krinke said: "This acquisition broadens our neuroscience leadership position with innovative brain modulation technology that, along with our comprehensive portfolio of DBS solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson’s disease and essential tremor."
Medtronic noted that both the firms will work to finalize product development and begin clinical research to integrate technologies into an expanded portfolio of DBS products within company’s Neuromodulation business.
In the US and Europe, Medtronic DBS therapy has received approval to treat disabling symptoms of essential tremor, advanced Parkinson’s disease and chronic intractable primary dystonia.
DBS therapy has also been approved to treat refractory epilepsy in the Europe, Canada and Australia.
